Last reviewed 2026-04-22 · How we verify

Chromogranin A

Chromogranin A is a neuroendocrine biomarker protein used for diagnostic and prognostic assessment rather than a therapeutic agent with a direct mechanism of action.

Chromogranin A is a neuroendocrine biomarker protein used for diagnostic and prognostic assessment rather than a therapeutic agent with a direct mechanism of action. Used for Diagnostic and prognostic biomarker for neuroendocrine neoplasms, Monitoring of carcinoid tumors and pheochromocytomas.

At a glance

Mechanism of action

Chromogranin A is an acidic secretory protein released by neuroendocrine cells and tumors. It serves as a diagnostic and prognostic biomarker for neuroendocrine neoplasms, carcinoid tumors, and pheochromocytomas, helping clinicians detect, monitor, and assess disease burden and treatment response. It is not a drug that acts on a molecular target but rather a measured biomarker in blood or tissue.

Approved indications

• Diagnostic and prognostic biomarker for neuroendocrine neoplasms
• Monitoring of carcinoid tumors and pheochromocytomas

Common side effects

No common side effects on file.

Key clinical trials

• Effect of Bed Bathing Methods on VRE Colonization in ICU Patients (NA)
• ATRX/DAXX in EUS-FNB Specimens of Pan-NETs
• Evaluation of Neuroendocrine Differentiation as a Potential Mechanism of Tumor Recurrence Following Radiotherapy
• Test for Pre Operative Skin Preparations (PHASE3)
• Catestatin as a Novel Biomarker for Cardiovascular and Microvascular Involvement in Systemic Sclerosis
• Pathogenesis of Periodontal Disease in Individuals With Psoriasis
• Salivary Stress Markers Associated With Malocclusion Severity
• Chlorhexidine Impregnated Cloths to Prevent Skin and Soft Tissue Infections in Marine Officer Candidates (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.